Investor Relations


Zogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
NASDAQ | ZGNX (Common Stock)
$9.13 + 0.05
Stock chart for: ZGNX.O.  Currently trading at $9.13 with a 52 week high of $21.03 and a 52 week low of $7.33.
Data as of 07/29/16 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest Presentations

Zogenix July 2016 Investor Presentation
Download Documentation

Recent News More

Zogenix Announces Agreement to Refinance Debt, Further Increasing Company’s Expected 2017 Cash Balance

Read More

Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome

Read More

Investor Events More

Tuesday, June 7, 2016 9:30 a.m. ET
Zogenix, Inc. at Jefferies 2016 Healthcare Conference
Tuesday, May 10, 2016 4:30 p.m. ET
Q1 2016 Zogenix, Inc. Earnings Conference Call